| The 5th edition of the World Health Organization classification of haematolymphoid tumours: lymphoid neoplasms R Alaggio, C Amador, I Anagnostopoulos, AD Attygalle, IBO Araujo, ... Leukemia 36 (7), 1720-1748, 2022 | 1668 | 2022 |
| Targeting cancer stemness in the clinic: from hype to hope C Saygin, D Matei, R Majeti, O Reizes, JD Lathia Cell stem cell 24 (1), 25-40, 2019 | 432 | 2019 |
| Dendritic cell sarcoma: a pooled analysis including 462 cases with presentation of our case series C Saygin, D Uzunaslan, M Ozguroglu, M Senocak, N Tuzuner Critical reviews in oncology/hematology 88 (2), 253-271, 2013 | 236 | 2013 |
| Emerging therapies for acute myeloid leukemia C Saygin, HE Carraway Journal of hematology & oncology 10, 1-14, 2017 | 151 | 2017 |
| Genomic determinants of chronic myelomonocytic leukemia BJ Patel, B Przychodzen, S Thota, T Radivoyevitch, V Visconte, ... Leukemia 31 (12), 2815-2823, 2017 | 99 | 2017 |
| CD55 regulates self-renewal and cisplatin resistance in endometrioid tumors C Saygin, A Wiechert, VS Rao, R Alluri, E Connor, PS Thiagarajan, ... Journal of Experimental Medicine 214 (9), 2715-2732, 2017 | 88 | 2017 |
| Cx26 drives self-renewal in triple-negative breast cancer via interaction with NANOG and focal adhesion kinase PS Thiagarajan, M Sinyuk, SM Turaga, EE Mulkearns-Hubert, JS Hale, ... Nature communications 9 (1), 578, 2018 | 77 | 2018 |
| Cisplatin induces stemness in ovarian cancer A Wiechert, C Saygin, PS Thiagarajan, VS Rao, JS Hale, N Gupta, ... Oncotarget 7 (21), 30511, 2016 | 69 | 2016 |
| Expression of MMP-1, MMP-9 and TIMP-2 in prostate carcinoma and their influence on prognosis and survival F Ozden, C Saygin, D Uzunaslan, B Onal, H Durak, H Aki Journal of cancer research and clinical oncology 139, 1373-1382, 2013 | 61 | 2013 |
| Therapy for lower-risk MDS HE Carraway, C Saygin Hematology 2014, the American Society of Hematology Education Program Book …, 2020 | 53 | 2020 |
| Current and emerging strategies for management of myelodysplastic syndromes C Saygin, HE Carraway Blood reviews 48, 100791, 2021 | 51 | 2021 |
| Mutations in DNMT3A, U2AF1, and EZH2 identify intermediate-risk acute myeloid leukemia patients with poor outcome after CR1 C Saygin, C Hirsch, B Przychodzen, MA Sekeres, BK Hamilton, ... Blood cancer journal 8 (1), 4, 2018 | 44 | 2018 |
| Impact of comorbidities on outcomes of elderly patients with diffuse large B‐cell lymphoma C Saygin, X Jia, B Hill, R Dean, B Pohlman, MR Smith, D Jagadeesh American journal of hematology 92 (10), 989-996, 2017 | 42 | 2017 |
| Therapy-related acute lymphoblastic leukemia is a distinct entity with adverse genetic features and clinical outcomes C Saygin, A Kishtagari, RD Cassaday, N Reizine, I Yurkiewicz, M Liedtke, ... Blood advances 3 (24), 4228-4237, 2019 | 39 | 2019 |
| A 17-year experience with ALL-BFM protocol in acute lymphoblastic leukemia: prognostic predictors and interruptions during protocol A Koka, C Saygin, D Uzunaslan, N Ozdemir, H Apak, T Celkan Leukemia research 38 (6), 699-705, 2014 | 33 | 2014 |
| New advances and challenges of targeting cancer stem cells NK Dashzeveg, R Taftaf, EK Ramos, L Torre-Healy, A Chumakova, ... Cancer research 77 (19), 5222-5227, 2017 | 30 | 2017 |
| No appreciable decrease in fertility in Behçet’s syndrome D Uzunaslan, C Saygin, G Hatemi, K Tascilar, H Yazici Rheumatology 53 (5), 828-833, 2014 | 30 | 2014 |
| Measurable residual disease in acute lymphoblastic leukemia: methods and clinical context in adult patients C Saygin, J Cannova, W Stock, L Muffly Haematologica 107 (12), 2783, 2022 | 28 | 2022 |
| Cedazuridine/decitabine: from preclinical to clinical development in myeloid malignancies AA Patel, K Cahill, C Saygin, O Odenike Blood Advances 5 (8), 2264-2271, 2021 | 28 | 2021 |
| Allogeneic hematopoietic stem cell transplant outcomes in adults with inherited myeloid malignancies C Saygin, G Roloff, CN Hahn, R Chhetri, S Gill, H Elmariah, C Talati, ... Blood Advances 7 (4), 549-554, 2023 | 26 | 2023 |
